Advanced in Febrile Neutropenia

Peter Klare

Berlin, BE, DE 
Advanced in Febrile Neutropenia
Berlin, BE, DE 
OverviewLocationsClinical Research

Overview

Peter Klare practices in Berlin, Germany. Mr. Klare is rated as an Advanced expert by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Breast Cancer, Colorectal Polyps, Triple-Negative Breast Cancer, Colonoscopy, and Endoscopy.

His clinical research consists of co-authoring 63 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Febrile Neutropenia.

Gender
Male

Locations

Berlin, BE, Germany
Other Locations
Hausham, BY, Germany
Munich, BY, Germany
Lichtenberg, BE 10367, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
Pazopanib Vs. Pazopanib Plus Gemcitabine in Patients with Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -
Pazopanib Vs. Pazopanib Plus Gemcitabine in Patients with Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -
Enrollment Status: Active_not_recruiting
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drugs: Pazopanib, Gemcitabine
Study Phase: Phase 2
Improvement of Colonoscopy Preparation by New Media (SMS) (PERICLES-II-Study)
Improvement of Colonoscopy Preparation by New Media (SMS) (PERICLES-II-Study)
Enrollment Status: Completed
Publish Date: April 21, 2017
Intervention Type: Procedure, Device
Study Phase: Not Applicable
View 2 Less Clinical Trials

63 Total Publications

RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: post-hoc analysis of the GeparOla trial.
RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: post-hoc analysis of the GeparOla trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 25, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Klare's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile